Adds Windchill+ as the only direct, full-stack SaaS PLM solution certified on the FedRAMP Marketplace Introduces Onshape Government Federal as the only cloud-native CAD and PDM solution for engineering teams working with CUI Expands PTC's FedRAMP portfolio as part of its long-term commitment to the federal market BOSTON, Nov. 19, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced an expansion of its FedRAMP offerings for U.S. federal agencies and contractors. PTC's Windchill+® product lifecycle management (PLM) solution is now available on Microsoft Azure Government within PTC Cloud Services, and PTC is introducing its Onshape® Government Federal solution, a FedRAMP Moderate Equivalent environment for engineering teams working with Controlled Unclassified Information (CUI).
PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be sustained.
Fisher Asset Management LLC raised its position in shares of PTC Inc. (NASDAQ: PTC) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 153,603 shares of the technology company's stock after acquiring an additional 11,076 shares
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of NVIDIA Corporation (NASDAQ: NVDA). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in NVIDIA stock on October 20th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative Gilbert Ray
BALA CYNWYD, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Data to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly patients with Sarcopenia and Sarcopenic Obesity Eos's merger with Pulmatrix, Inc. anticipated to close in Q4 2026, subject to Nasdaq listing approval and customary closing conditions HOUSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today announced it will present new data from a pre-clinical study of its lead MitoXcel™ geropeptide, PTC-2105, at the 19th Sarcopenia, Cachexia & Wasting Disorders International Conference (SCWD), taking place December 10-12, 2026 in Washington, D.C. Eos's presentation was recently upgraded from a poster presentation to a plenary presentation in the Rapid Fire Abstract Session to be held on December 11, 2026, at 9:35 am.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of PTC Inc. (NASDAQ: PTC) to Schneider Electric for $205.00 per share in cash.Halper Sadeh encourages PTC shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether PTC and its board of directors violated the federal securiti.
While the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PTC's Q4 fiscal 2026 earnings and revenues beat estimates, while ARR growth remain strong despite revenue declines and divestiture-related pressures.
PTC Inc. (PTC) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $3.47 per share a year ago.